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Background
Overcoming resistance to treatment is an essential issue in many cancers including
glioblastoma (GBM), the deadliest primary tumor of the central nervous system. As
dependence on iron is a key feature of tumor cells, using chelators to reduce iron
represents an opportunity to improve conventional GBM therapies. The aim of the
present study was, therefore, to investigate the cytostatic and cytotoxic impact of the
new iron chelator deferasirox (DFX) on human GBM cells in well-defined clinical
situations represented by radiation therapy and mild-hypoxia.
Results
Under experimental normoxic condition (21 % O2), deferasirox (DFX) used at 10 μM
for 3 days reduced proliferation, led cell cycle arrest in S and G2-M phases and
induced cytotoxicity and apoptosis in U251 and U87 GBM cells. The abolition of the
antineoplastic DFX effects when cells were co-treated with ferric ammonium sulfate
supports the hypothesis that its effects result from its ability to chelate iron. As
radiotherapy is the main treatment for GBM, the combination of DFX and X-ray beam
irradiation was also investigated. Irradiation at a dose of 16 Gy repressed
proliferation, cytotoxicity and apoptosis, but only in U251 cells, while no synergy with
DFX was observed in either cell line. Importantly, when the same experiment was
conducted in mild-hypoxic conditions (3 % O2), the antiproliferative and cytotoxic
effects of DFX were abolished, and its ability to deplete iron was also impaired.
Conclusions
Taken together, these in vitro results could raise the question of the benefit of using
iron chelators in their native forms under the hypoxic conditions often encountered in
solid tumors such as GBM. Developing new chemistry or a new drug delivery system
that would keep DFX active in hypoxic cells may be the next step toward their
application.
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